Neurology Alert – September 1, 2019
September 1, 2019
View Issues
-
Antisense Oligonucleotide Treatment of Huntington’s Disease: A Novel Potential Treatment
In this Phase I/IIa clinical trial, investigators administered antisense huntingtin oligonucleotides intrathecally to patients with early Huntington’s disease (HD), and demonstrated safety, tolerability, and dose-dependent reduction in CSF mutant huntingtin. This approach now is being tested for clinical efficacy in HD in a Phase III clinical trial.
-
Calcitonin Gene-Related Peptide Targeting Therapies for Migraine
Two randomized clinical trials showed that calcitonin gene-related peptide targeting therapies are effective and safe for primary headache disorders.
-
Targeting Fyn Kinase in Alzheimer’s Disease: Another Failed Clinical Trial
In this multicenter Phase IIa clinical trial in mild Alzheimer’s disease dementia, the tyrosine kinase Fyn inhibitor AZD0540 had no significant effects after 52 weeks of treatment.
-
Risk of Neuropathy With Fluoroquinolones
As a class, fluoroquinolones are some of the most commonly used antibiotics worldwide. Their use carries a significant risk of neurotoxicty, for both the peripheral and central nervous system.
-
Racial and Ethnic Disparities in Thrombectomy in the United States
-
After Ischemic Stroke Related to Atrial Fibrillation, Direct Oral Anticoagulants Are Superior to Vitamin K Antagonists
-
Faster Time to Endovascular Reperfusion Therapy Results in Better Outcomes